Journal
AMERICAN JOURNAL OF MEDICINE
Volume 123, Issue 4, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2009.07.017
Keywords
Diabetes mellitus; Drug toxicity; Risk assessment; Safety; Therapeutics
Categories
Funding
- Amylin Pharmaceuticals, Inc.
Ask authors/readers for more resources
The selection of appropriate pharmacologic therapy for any disease requires a careful assessment of benefit and risk. In the case of type 2 diabetes, this decision typically balances the benefits accrued from improved glycemic control with the risks inherent in glucose-lowering medications. This review is intended to assist therapeutic decision-making by carefully assessing the potential benefit from improved metabolic control relative to the potential risks of a wide array of currently prescribed glucose-lowering agents. Wherever possible, risks and benefits have been expressed in terms of absolute rates (events per 1000 patient-years) to facilitate cross-study comparisons. The review incorporates data from new studies (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation, Action to Control Cardiovascular Risk in Diabetes, and the Veterans Affairs Diabetes Trial), as well as safety issues associated with newer glucose-lowering medications. (C) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 374.e9-374.e18
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available